EIAab
首页  >  重组蛋白  >  Human EGFR Recombinant Protein
EGFR (基因名), Epidermal growth factor receptor (蛋白名), egfr_human.
产品名称:

Human EGFR/ Epidermal growth factor receptor Recombinant Protein
表皮生长因子受体

货号:

R0757h

商标:
EIAab®
监管等级:
别名:

Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, ERBB, ERBB1, HER1

序列号:
P00533
来源:
E.coli
种属:
Human
标签:
His
序列:
291-534aa
预估分子量:
26.84 kDa (monomer)
纯度:
Greater than 98% by SDS-PAGE
浓度:
Reconstitution Dependent
形态:
Liquid
内毒素水平:
Please contact protein@eiaab.com The technician for more information.
应用:
存储缓冲液:
50mM NaH2PO4, 500mM NaCl Buffer with 500mM Imidazole, 10%glycerol(PH8.0)
存储:
Store at -20°C. (Avoid repeated freezing and thawing.)
研究领域:
Cancer
  • Human EGFR Protein
  • Human EGFR Protein
  • Human EGFR Protein
规格 & 价格: cart
×
Human EGFR Protein
邮箱 *
消息 *
Please 登录.
产品说明书
数据表: 下载说明书
MSDS: MSDS
在线询价


R&D 技术数据
Human EGFR Protein
The PCR product of human EGFR gene was determined by 1% Agarose stained with EB.
Human EGFR Protein
Recombinant human EGFR protein was determined by 12% SDS-PAGE stained with Coomassie Blue under reducing conditions.
基因位点
Cytogenetic band: 7p11.2 by HGNC 7p11.2 by Entrez Gene 7p11.2 by Ensembl
EGFR Gene in genomic location: bands according to Ensembl, locations according to GeneLoc (and/or Entrez Gene and/or Ensembl if different)
基因位点
通用注释


亚单元:
Binding of the ligand triggers homo- and/or heterodimerization of the receptor triggering its autophosphorylation. Heterodimer with ERBB2. Interacts with ERRFI1; inhibits dimerization of the kinase domain and autophosphorylation. Part of a complex with ERBB2 and either PIK3C2A or PIK3C2B. Interacts with GRB2; an adapter protein coupling the receptor to downstream signaling pathways. Interacts with GAB2; involved in signaling downstream of EGFR. Interacts with STAT3; mediates EGFR downstream signaling in cell proliferation. Interacts with RIPK1; involved in NF-kappa-B activation. Interacts (autophosphorylated) with CBL, CBLB and CBLC; involved in EGFR ubiquitination and regulation. Interacts with SOCS5; regulates EGFR degradation through ELOC- and ELOB-mediated ubiquitination and proteasomal degradation. Interacts with PRMT5; methylates EGFR and enhances interaction with PTPN6. Interacts (phosphorylated) with PTPN6; inhibits EGFR-dependent activation of MAPK/ERK. Interacts with COPG1; essential for regulation of EGF-dependent nuclear transport of EGFR by retrograde trafficking from the Golgi to the ER. Interacts with TNK2; this interaction is dependent on EGF stimulation and kinase activity of EGFR. Interacts with PCNA; positively regulates PCNA. Interacts with PELP1. Interacts with MUC1. Interacts with AP2M1. Interacts with FER. May interact with EPS8; mediates EPS8 phosphorylation. Interacts (via SH2 domains) with GRB2, NCK1 and NCK2. Interacts with ATX2. Interacts with GAREM1. Interacts (ubiquitinated) with ANKRD13A/B/D; the interaction is direct and may regulate EGFR internalization after EGF stimulation. Interacts with GPER1; the interaction occurs in an estrogen-dependent manner. Interacts (via C-terminal cytoplasmic kinase domain) with ZPR1 (via zinc fingers). Interacts with RNF115 and RNF126. Interacts with GPRC5A (via its transmembrane domain)(PubMed:25311788). Interacts with FAM83B; positively regulates EGFR inducing its autophospharylation in absence of stimulation by EGF (PubMed:23912460).


功能:
Isoform 2 may act as an antagonist of EGF action.


亚细胞位置:
Isoform 2 Secreted



[1].
"Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers."

[2].
"A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer."

[3].
"Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6."

[4].
"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial."

[5].
"Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment."
关闭
Sample Data
关闭
Sample Data
关闭
Sample Data
用户中心 close
购物车 close
我的收藏 close
我的足迹 close
清除
产品对比 close
用户中心
购物车
我的收藏
我的足迹
产品对比
回到顶部
通知
new 咨询
规格 数量 单价 (¥) 小计 1 (¥)
小计 2:
triangle
规格 数量 单价 (¥)
你想做我们的代理并得到更低的折扣吗?
请联系我们:
电话:027-59234612(+86)
传真:027-59234610(+86)
邮箱:sales@eiaab.com